MEDICLIN AG (MED.DE) Stock Fundamental Analysis

FRA:MED • DE0006595101

3.96 EUR
+0.1 (+2.59%)
Last: Feb 27, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

6

Taking everything into account, MED scores 6 out of 10 in our fundamental rating. MED was compared to 32 industry peers in the Health Care Providers & Services industry. MED scores excellent on profitability, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on MED.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • MED had positive earnings in the past year.
  • In the past year MED had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: MED reported negative net income in multiple years.
  • In the past 5 years MED always reported a positive cash flow from operatings.
MED.DE Yearly Net Income VS EBIT VS OCF VS FCFMED.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 3.85%, MED is in the better half of the industry, outperforming 68.75% of the companies in the same industry.
  • MED's Return On Equity of 14.15% is fine compared to the rest of the industry. MED outperforms 78.13% of its industry peers.
  • MED's Return On Invested Capital of 7.06% is fine compared to the rest of the industry. MED outperforms 71.88% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for MED is below the industry average of 6.99%.
  • The 3 year average ROIC (3.46%) for MED is below the current ROIC(7.06%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.85%
ROE 14.15%
ROIC 7.06%
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
MED.DE Yearly ROA, ROE, ROICMED.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10

1.3 Margins

  • MED has a better Profit Margin (4.40%) than 71.88% of its industry peers.
  • In the last couple of years the Profit Margin of MED has grown nicely.
  • Looking at the Operating Margin, with a value of 8.52%, MED is in the better half of the industry, outperforming 71.88% of the companies in the same industry.
  • In the last couple of years the Operating Margin of MED has grown nicely.
  • With an excellent Gross Margin value of 84.08%, MED belongs to the best of the industry, outperforming 81.25% of the companies in the same industry.
  • In the last couple of years the Gross Margin of MED has remained more or less at the same level.
Industry RankSector Rank
OM 8.52%
PM (TTM) 4.4%
GM 84.08%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
MED.DE Yearly Profit, Operating, Gross MarginsMED.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MED is still creating some value.
  • Compared to 1 year ago, MED has about the same amount of shares outstanding.
  • MED has about the same amout of shares outstanding than it did 5 years ago.
  • The debt/assets ratio for MED has been reduced compared to a year ago.
MED.DE Yearly Shares OutstandingMED.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MED.DE Yearly Total Debt VS Total AssetsMED.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of 1.60, we must say that MED is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of 1.60, MED perfoms like the industry average, outperforming 43.75% of the companies in the same industry.
  • MED has a debt to FCF ratio of 9.63. This is a negative value and a sign of low solvency as MED would need 9.63 years to pay back of all of its debts.
  • MED's Debt to FCF ratio of 9.63 is in line compared to the rest of the industry. MED outperforms 53.13% of its industry peers.
  • MED has a Debt/Equity ratio of 1.69. This is a high value indicating a heavy dependency on external financing.
  • MED has a Debt to Equity ratio of 1.69. This is in the lower half of the industry: MED underperforms 62.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.69
Debt/FCF 9.63
Altman-Z 1.6
ROIC/WACC1.44
WACC4.89%
MED.DE Yearly LT Debt VS Equity VS FCFMED.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.93 indicates that MED should not have too much problems paying its short term obligations.
  • The Current ratio of MED (1.93) is better than 87.50% of its industry peers.
  • A Quick Ratio of 1.89 indicates that MED should not have too much problems paying its short term obligations.
  • With an excellent Quick ratio value of 1.89, MED belongs to the best of the industry, outperforming 90.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.89
MED.DE Yearly Current Assets VS Current LiabilitesMED.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 414.18% over the past year.
  • Measured over the past years, MED shows a very strong growth in Earnings Per Share. The EPS has been growing by 20.79% on average per year.
  • Looking at the last year, MED shows a small growth in Revenue. The Revenue has grown by 3.40% in the last year.
  • Measured over the past years, MED shows a small growth in Revenue. The Revenue has been growing by 2.19% on average per year.
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%

3.2 Future

  • Based on estimates for the next years, MED will show a very strong growth in Earnings Per Share. The EPS will grow by 22.30% on average per year.
  • The Revenue is expected to grow by 3.41% on average over the next years.
EPS Next Y78.05%
EPS Next 2Y34.35%
EPS Next 3Y22.3%
EPS Next 5YN/A
Revenue Next Year5.81%
Revenue Next 2Y4.12%
Revenue Next 3Y3.41%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MED.DE Yearly Revenue VS EstimatesMED.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
MED.DE Yearly EPS VS EstimatesMED.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

9

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 5.35, which indicates a rather cheap valuation of MED.
  • Compared to the rest of the industry, the Price/Earnings ratio of MED indicates a rather cheap valuation: MED is cheaper than 100.00% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of MED to the average of the S&P500 Index (27.10), we can say MED is valued rather cheaply.
  • MED is valuated cheaply with a Price/Forward Earnings ratio of 5.30.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MED indicates a rather cheap valuation: MED is cheaper than 100.00% of the companies listed in the same industry.
  • MED's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.06.
Industry RankSector Rank
PE 5.35
Fwd PE 5.3
MED.DE Price Earnings VS Forward Price EarningsMED.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • MED's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MED is cheaper than 96.88% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, MED is valued cheaper than 87.50% of the companies in the same industry.
Industry RankSector Rank
P/FCF 4.05
EV/EBITDA 2.94
MED.DE Per share dataMED.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • MED has a very decent profitability rating, which may justify a higher PE ratio.
  • MED's earnings are expected to grow with 22.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.07
PEG (5Y)0.26
EPS Next 2Y34.35%
EPS Next 3Y22.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

2

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 1.08%, MED has a reasonable but not impressive dividend return.
  • MED's Dividend Yield is comparable with the industry average which is at 1.65.
  • Compared to the average S&P500 Dividend Yield of 1.80, MED is paying slightly less dividend.
Industry RankSector Rank
Dividend Yield 1.08%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
MED.DE Yearly Dividends per shareMED.DE Yearly Dividends per shareYearly Dividends per share 2019 2025 0.01 0.02 0.03 0.04

5.3 Sustainability

DPN/A
EPS Next 2Y34.35%
EPS Next 3Y22.3%
MED.DE Yearly Income VS Free CF VS DividendMED.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

More info and screens

Find the best dividend stocksShow peers with best dividend

MEDICLIN AG

FRA:MED (2/27/2026, 7:00:00 PM)

3.96

+0.1 (+2.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-04
Earnings (Next)03-26
Inst Owners0.96%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap188.10M
Revenue(TTM)797.34M
Net Income(TTM)35.05M
Analysts80
Price Target5.87 (48.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.08%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.34%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)16.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.72%
Revenue NY rev (3m)1.2%
Valuation
Industry RankSector Rank
PE 5.35
Fwd PE 5.3
P/S 0.24
P/FCF 4.05
P/OCF 1.95
P/B 0.76
P/tB 0.84
EV/EBITDA 2.94
EPS(TTM)0.74
EY18.69%
EPS(NY)0.75
Fwd EY18.87%
FCF(TTM)0.98
FCFY24.72%
OCF(TTM)2.04
OCFY51.39%
SpS16.79
BVpS5.21
TBVpS4.7
PEG (NY)0.07
PEG (5Y)0.26
Graham Number9.32
Profitability
Industry RankSector Rank
ROA 3.85%
ROE 14.15%
ROCE 9.1%
ROIC 7.06%
ROICexc 9.61%
ROICexgc 10.05%
OM 8.52%
PM (TTM) 4.4%
GM 84.08%
FCFM 5.83%
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexgc growth 3Y64.29%
ROICexgc growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 1.69
Debt/FCF 9.63
Debt/EBITDA 3.49
Cap/Depr 96.09%
Cap/Sales 6.29%
Interest Coverage 3.18
Cash Conversion 80.47%
Profit Quality 132.66%
Current Ratio 1.93
Quick Ratio 1.89
Altman-Z 1.6
F-Score8
WACC4.89%
ROIC/WACC1.44
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
EPS Next Y78.05%
EPS Next 2Y34.35%
EPS Next 3Y22.3%
EPS Next 5YN/A
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
Revenue Next Year5.81%
Revenue Next 2Y4.12%
Revenue Next 3Y3.41%
Revenue Next 5YN/A
EBIT growth 1Y281.51%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year143.72%
EBIT Next 3Y33.62%
EBIT Next 5YN/A
FCF growth 1Y196.83%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.85%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%

MEDICLIN AG / MED.DE FAQ

What is the ChartMill fundamental rating of MEDICLIN AG (MED.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to MED.DE.


Can you provide the valuation status for MEDICLIN AG?

ChartMill assigns a valuation rating of 9 / 10 to MEDICLIN AG (MED.DE). This can be considered as Undervalued.


Can you provide the profitability details for MEDICLIN AG?

MEDICLIN AG (MED.DE) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for MED stock?

The Price/Earnings (PE) ratio for MEDICLIN AG (MED.DE) is 5.35 and the Price/Book (PB) ratio is 0.76.


What is the financial health of MEDICLIN AG (MED.DE) stock?

The financial health rating of MEDICLIN AG (MED.DE) is 4 / 10.